

ERRATUM

Open Access



Erratum to: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids

Christian Vogelberg^{1*}, Petra Moroni-Zentgraf², Migle Leonaviciute-Klimantaviciene³, Ralf Sigmund⁴, Eckard Hamelmann⁵, Michael Engel² and Stanley Szeffler⁶

Erratum

Following publication of our article [1] we identified an error in Fig. 5, where results were inadvertently switched between morning and evening PEF responses. The corrected Fig. 5 is provided in this erratum. The PEF results provided in our original article text remain correct.

Author details

¹University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany. ²Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany. ³Vilnius University Hospital, Vilnius, Lithuania. ⁴Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany. ⁵Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany. ⁶Department of Pediatrics, Children's Hospital of Colorado and the University of Colorado Denver School of Medicine, Aurora, Colorado, USA.

Received: 12 October 2015 Accepted: 12 October 2015

Published online: 20 October 2015

Reference

1. Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Hamelmann E, Engel M, et al. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids. *Respir Res.* 2015;16:20.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



* Correspondence: christian.vogelberg@uniklinikum-dresden.de
¹University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany




Fig. 5 Morning and evening PEF response after 4 weeks of treatment (full analysis set). Adjusted for 'treatment', 'period', 'patient' and 'baseline'. *p < 0.05 versus placebo Respimat®. PEF, peak expiratory flow